USE OF PSYCHEDELIC SUBSTANCES FOR THERAPEUTIC PURPOSES: IATROGENIC PROBLEM OR JUSTIFIED NECESSITY? PART 1


Cite item

Full Text

Abstract

Hallucinogenic substances are usually classified into several different classes. Most classifications are based on the pharmacological mechanisms of action of these substances and their chemical structure. Psychedelics, entactogens, dissociative substances and “atypical” hallucinogens belongs to chemically heterogeneous group of substances with a hallucinogenic effect. All of the above classes of substances basically do not have common primary mechanisms of action. At the same time, they are similar in the ability to cause temporary, different in depth changes in consciousness, combined with changes in somatic status, perception, cognitive processes, and the emotions. Similar changes contribute to the recreational use of substances of this group. In recent years, a large number of works have appeared in the scientific literature, indicating the possibility of using these substances for therapeutic purposes. This review presents current literature data on several classes of hallucinogens, the therapeutic use of which is documented as much as possible.

About the authors

Azat R Asadullin

Bashkir State Medical University

Email: droar@yandex.ru
Ufa, 3 Lenin Street

Andrey V Antsyborov

Medical Center «Alpha Health Center»

Email: andrei.v.ancyborov@gmail.com
Rostov-on-Don, Socialistic str., 154 «a»

References

  1. Abramson H.A., Rolo A. Comparison of LSD with methysergide and psilocybin on test subjects / The Use of LSD in Psychotherapy and Alcoholism, ed. Abramson, HA. 1967. С. 53-73
  2. Aghajanian G.K., Marek G.J. Serotonin and hallucino-gens // Neuropsychopharmacology. 1999. Vol. 21 (Suppl, 2). P. 16S-23S
  3. Albaugh B.J., Anderson P.O. Peyote in the treatment of alcoholism among American Indians // American journal of Psychiatry. 1974. Vol. 131, № 11. P. 1247-1250
  4. Asadullin A.R. et al. Approach to Classifying “Design” Drugs and New Potentially Dangerous Chemical Substances, with a Brief Review of the Problem // International Journal of Environmental and Science Education. 2016. Vol. 11, № 14. С. 6697-6703
  5. Auerbach R., Rugowski J.A. Lysergic acid diethylamide: effect on embryos // Science. 1967. Vol. 157, № 3794. P. 1325-1326
  6. Baggott M. J. et al. Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire // Drug & Alcohol Dependence. 2011. Vol. 114, № 1. P. 61-67
  7. Bergman R. L. Navajo peyote use: Its apparent safety // American Journal of Psychiatry. 1971. Vol. 128, №. 6. P. 695-699
  8. Bergquist L. The curious story behind the new Cary Grant // Look, September. 1959. Vol. 1
  9. Bogenschutz M.P. et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study // Journal of psychopharmacology. 2015. Vol. 29, № 3. P. 289-299
  10. Brodie B. B., Shore P. A. A concept for a role of serotonin and norepinephrine as chemical mediators in the brain // Annals of the New York Academy of Sciences. 1957. Vol. 66, № 1. P. 631-642
  11. Bruhn J.G. et al. Mescaline use for 5700 years // The Lancet. 2002. Vol. 359, № 9320. P. 1866
  12. Carbonaro T.M. et al. The role of 5-HT 2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N, N-dimethyltryptamine and N, N-diisopropyltryptamine in rats and mice // Psychopharmacology. 2014. Vol. 232, № 1. P. 275-284
  13. Carhart-Harris R.L. et al. LSD enhances suggestibility in healthy volunteers // Psychopharmacology. 2014_a. Vol. 232, №. 4. P. 785-794
  14. Carhart-Harris R.L. et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin // Proceedings of the National Academy of Sciences. 2012. Vol. 109, №. 6. P. 2138-2143
  15. Carhart-Harris R.L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study // The Lancet Psychiatry. 2016. Vol. 3, № 7. P. 619-627
  16. Carhart-Harris R.L., Nutt D.J. Experienced drug users assess the relative harms and benefits of drugs: a web-based survey // Journal of psychoactive drugs. 2013. Vol. 45, № 4. P. 322-328
  17. Caudevilla-Gálligo F. et al. 4-Bromo-2, 5-dimethoxy-phenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects // Journal of Psychopharmacology. 2012. Vol. 26, № 7. P. 1026-1035
  18. Chwelos N. et al. Use of d-lysergic acid diethylamide in the treatment of alcoholism // Quarterly journal of studies on alcohol. 1959. Vol. 20. P. 577-590
  19. Cohen M.M., Marinello M.J., Back N. Chromosomal damage in human leukocytes induced by lysergic acid diethylamide // Science. 1967. Vol. 155, № 3768. P. 1417-1419
  20. Cohen M.M., Shiloh Y. Genetic toxicology of lysergic acid diethylamide (LSD-25) // Mutation Research/Reviews in Genetic Toxicology. 1977. Vol. 47, № 3-4. P. 183-209
  21. Cohen S. Lysergic Acid Diethylamide //The Journal of nervous and mental disease. 1960. Vol. 130, №. 1. P. 30-40
  22. Cohen S. The therapeutic potential of LSD-25 / A Pharmacologic Approach to the Study of the Mind [eds. RM Featherstone and A. Simon]. Springfield, Ill.: Thomas, 1959
  23. Cozzi N. V. Psychedelic breakthroughs in neuroscience: How psychedelic drugs influenced the growth and development of psychopharmacology // MAPS Bulletin. 2013. Vol. 23, № 1. P. 16-19
  24. de Verges G. Constitutional Law: Freedom of Religion: Peyote and the Native American Church // American Indian Law Review. 1974. Т. 2, № 2. С. 71-79
  25. Deniker P. Biological changes in man following intravenous administration of mescaline // The Journal of nervous and mental disease. 1957. Т. 125, № 3. С. 427-431
  26. Dishotsky N.I. et al. LSD and genetic damage // Science. 1971. Vol. 172, № 3982. P. 431-440
  27. Doblin R. Pahnke’s “Good Friday Experiment”: A long-term follow-up and methodological critique // The Journal of Transpersonal Psychology. 1991. Vol. 23, № 1. P. 1
  28. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression // Brain structure and function. 2008. Vol. 213, № 1-2. P. 93-118
  29. Duncan D.F., Gold R.S. Drugs and the whole person. Macmillan Publishing Company, 1982
  30. Dyck E. Flashback: psychiatric experimentation with LSD in historical perspective // The Canadian Journal of Psychiatry. 2005. Vol. 50, №. 7. P. 381-388
  31. Egozcue J., Irwin S., Maruffo C. A. Chromosomal damage in LSD users // Jama. 1968. Vol. 204, № 3. P. 214-218
  32. Eisner B.G., Cohen S. Psychotherapy with lysergic acid diethylamide, 1958
  33. El-Seedi H.R. et al. Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas // Journal of ethnopharmacology. 2005. Vol. 101, №. 1-3. P. 238-242
  34. Evarts E.V. A review of the neurophysiological effects of lysergic acid diethylamide (LSD) and other psychotomimetic agents // Annals of the New York Academy of Sciences. 1957. Vol. 66, № 1. P. 479-495
  35. Fadiman J. The psychedelic explorer’s guide: Safe, therapeutic, and sacred journeys. Simon and Schuster, 2011
  36. Faillace L.A., Snyder S.H., Weingartner H. 2, 5-dimethoxy-4-methylamphetamine: clinical evaluation of a new hallucinogenic drug // Journal of Nervous and Mental Disease. 1970
  37. Fantegrossi W.E., Murnane K.S., Reissig C.J. The behavioral pharmacology of hallucinogens // Biochemical pharmacology. 2008. Vol. 75, № 1. P. 17-33
  38. Fantegrossi W. E., Woods J. H., Winger G. Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys // Behavioural pharmacology. 2004. Vol. 15, № 2. P. 149-157
  39. Garcia-Romeu A., Griffiths R., Johnson M. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction // Current drug abuse reviews. 2014. Vol. 7, № 3. P. 157-164
  40. Garrity J.F. Jesus, peyote, and the holy people: alcohol abuse and the ethos of power in Navajo healing // Medical Anthropology Quarterly. 2000. Vol. 14, №4. P. 521-542
  41. Gasser P. et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases // The Journal of nervous and mental disease. 2014. Vol. 202, № 7. P. 513
  42. Gasser P., Kirchner K., Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects // Journal of Psychopharmacology. 2014_b. Vol. 29, № 1. P. 57-68
  43. Geyer M.A. Lysergic acid diethylamide and psilocybin revisited // Biological psychiatry. 2015. Vol. 78, № 8. P. 516-518
  44. Glass G.S., Bowers M.B. Chronic psychosis associated with long-term psychotomimetic drug abuse // Archives of general psychiatry. 1970. Vol. 23, № 2. P. 97-103
  45. Glennon R.A., Young R., Rosecrans J.A. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists // European journal of pharmacology. 1983. Vol. 91, № 2-3. P. 189-196
  46. Greiner T., Burch N. R., Edelberg R. Psychopathology and psychophysiology of minimal LSD-25 dosage: A preliminary dosage-response spectrum // AMA Archives of Neurology & Psychiatry. 1958. Vol. 79, № 2. P. 208-210
  47. Griffiths R.R. et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later // Journal of psychopharmacology. 2008. Vol. 22, № 6. P. 621-632
  48. Griffiths R.R. et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance // Psychopharmacology. 2006. Vol. 187, № 3. P. 268-283
  49. Griffiths R.R. et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects // Psychopharmacology. 2011. Vol. 218, № 4. P. 649-665
  50. Grinspoon L., Bakalar J. B. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research // Journal of psychoactive drugs. 1997. Vol. 30, № 2. P. 171-177
  51. Grob C.S. et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer // Archives of general psychiatry. 2011. Vol. 68, № 1. P. 71-78
  52. Grof S. et al. LSD-assisted psychotherapy in patients with terminal cancer // International pharmacopsychiatry. 1972. Vol. 8. P. 129-144
  53. Guerra-Doce E. Psychoactive substances in prehistoric times: examining the archaeological evidence // Time and Mind. 2015. Vol. 8, № 1. P. 91-112
  54. Halberstadt A. L. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens // Behavioural brain research. 2014. Vol. 277. P. 99-120
  55. Halpern J.H. et al. Psychological and cognitive effects of long-term peyote use among Native Americans // Biological psychiatry. 2005. Vol. 58, № 8. P. 624-631
  56. Halpern J.H., Pope H.G. Hallucinogen persisting perception disorder: what do we know after 50 years? // Drug & Alcohol Dependence. 2003. Vol. 69, № 2. P. 109-119
  57. Harman W.W. et al. Psychedelic agents in creative problem-solving: A pilot study // Psychological reports. 1966. Vol. 19, № 1. P. 211-227
  58. Heffter A. Ueber Cacteenalkaloi // der. Ber Dtsch Chem Ges. 1896. Vol. 29, № 216. P. 27
  59. Hermle L. et al. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research // Biological psychiatry. 1992. Vol. 32, № 11. P. 976-991
  60. Hermle L., Gouzoulis-Mayfrank E., Spitzer M. Blood flow and cerebral laterality in the mescaline model of psychosis // Pharmacopsychiatry. 1998. Vol. 31, № S 2. P. 85-91
  61. Hoffmeister F., Wuttke W. Psychotropic drugs as negative reinforces // Pharmacological reviews. 1975. Vol. 27, № 3. P. 419-428
  62. Hofmann A. et al. Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rausch pilz Psilocybe mexicana Heim // Experientia. 1958. Vol. 14, № 3. P. 107-109
  63. Hofmann A. How LSD originated // Journal of psychedelic drugs. 1979. Vol. 11, № 1-2. P. 53-60
  64. Hofmann A. LSD: my problem child. Oxford University Press, 2013
  65. Hollister L.E., Hartman A.M. Mescaline, lysergic acid diethylamide and psilocybin: comparison of clinical syndromes, effects on color perception and biochemical measures // Comprehensive Psychiatry. 1962. Vol. 3, № 4. P. 235-241
  66. Isbell H. Comparison of the reactions induced by psilocybin and LSD-25 in man // Psychopharmacology. 1959. Vol. 1, № 1. P. 29-38
  67. Isbell H. et al. Studies on lysergic acid diethylamide (LSD-25): 1. Effects in former morphine addicts and development of tolerance during chronic intoxication // AMA Archives of Neurology & Psychiatry. 1956. Vol. 76, № 5. P. 468-478
  68. Isbell H. et al. Studies on lysergic acid diethylamide (LSD-25): 1. Effects in former morphine addicts and development of tolerance during chronic intoxication // AMA Archives of Neurology & Psychiatry. 1956. Vol. 76, № 5. P. 468-478
  69. Johnson M.W. et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction // Journal of psychopharmacology. 2014. Vol. 28, № 11. P. 983-992
  70. Johnson M.W., Richards W. A., Griffiths R.R. Human hallucinogen research: guidelines for safety // Journal of psychopharmacology. 2008. Vol. 22, № 6. P. 603-620
  71. Johnson M.W., Sewell R.A., Griffiths R.R. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers // Drug & Alcohol Dependence. 2012. Vol. 123, № 1. P. 132-140
  72. Kaelen M. et al. LSD enhances the emotional response to music // Psychopharmacology. 2015. Vol. 232, № 19. P. 3607-3614
  73. Kast E.C., Collins V.J. Study of lysergic acid diethylamide as an analgesic agent // Anesthesia & Analgesia. 1964. Vol. 43, № 3. P. 285-291
  74. Katz S. My 12 hours as a madman // Maclean’s. 1953. Vol. 108, № 52. P. 69-70
  75. Keeler M.H., Ewing J.A., Rouse B.A. Hallucinogenic effects of marijuana as currently used // American Journal of Psychiatry. 1971. Vol. 128, № 2. P. 213-216
  76. Kirsch I., Low C.B. Suggestion in the treatment of depression // American Journal of Clinical Hypnosis. 2013. Vol. 55, № 3. P. 221-229
  77. Kraehenmann R. et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers // Biological psychiatry. 2014. Vol. 78, № 8. P. 572-581
  78. Krebs T.S., Johansen P.Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials // Journal of Psychopharmacology. 2012. Vol. 26, № 7. P. 994-1002
  79. Leary T., Litwin G.H., Metzner R. Reactions to psilocybin administered in a supportive environment // Journal of Nervous and Mental Disease. 1963
  80. Lee M.A., Shlain B. Acid dreams: The complete social history of LSD: The CIA, the sixties, and beyond. Grove Press, 1992
  81. Lewin L. Phantastica: narcotic and stimulating drugs, their use and abuse, 1931
  82. Li H.L. An archaeological and historical account of cannabis in China // Economic Botany. 1973. Vol. 28, № 4. P. 437-448
  83. MacLean K.A., Johnson M.W., Griffiths R.R. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness // Journal of Psychopharmacology. 2011. Vol. 25, № 11. P. 1453-1461
  84. Malitz S. et al. Some observations on psilocybin, a new hallucinogen, in volunteer subjects // Comprehensive psychiatry. 1960
  85. Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research // Journal of psychoactive drugs. 1998. Vol. 30, № 4. p. 381-418
  86. Mashour G.A. From LSD to the IRB: Henry Beecher’s psychedelic research and the foundation of clinical ethics // International anesthesiology clinics. 2007. Vol. 45, № 4. P. 105-111
  87. Masters R., Houston J. The varieties of psychedelic experience: The classic guide to the effects of LSD on the human psyche. Simon and Schuster, 2000
  88. McGlothlin W.H., Arnold D.O. LSD revisited: A ten-year follow-up of medical LSD use // Archives of General Psychiatry. 1971. Vol. 24, №. 1. P. 35-49
  89. McGlothlin W., Cohen S., McGlothlin M.S. Long lasting effects of LSD on normal // Archives of General Psychiatry. 1967. Vol. 17, № 5. P. 521-532
  90. McKenna D., Riba J. New World tryptamine hallucinogens and the neuroscience of ayahuasca. 2015
  91. McKinney C.H. et al. Effects of guided imagery and music (GIM) therapy on mood and cortisol in healthy adults // Health psychology. 1997. Vol. 16, № 4. P. 390
  92. Metzner R. Teonanacatl: sacred mushroom of visions // Four Tree, El Verano, CA. 2004. Vol. 25
  93. Moreno F. A. et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder // Journal of Clinical Psychiatry. 2006. Vol. 67, № 11. P. 1735-1740
  94. Moreno J.L. et al. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists // Neuroscience letters. 2011. Vol. 493, № 3. P. 76-79
  95. Morris H., Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs // Drug testing and analysis. 2014. Т. 6, № 7-8. P. 614-632
  96. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens // Journal of psychoactive drugs. 1986. Vol. 18, № 4. P. 305-313
  97. Nichols D. E. Hallucinogens // Pharmacology & therapeutics. 2004. Vol. 101, № 2. P. 131-181
  98. Nichols D. E. Psychedelics // Pharmacological reviews. 2016. Vol. 68, № 2. P. 264-355
  99. Nutt D.J. et al. Drug harms in the UK: a multicriteria decision analysis // The Lancet. 2010. Vol. 376, № 9752. P. 1558-1565
  100. Nutt D. J., King L. A., Nichols D. E. Effects of Schedule I drug laws on neuroscience research and treatment innovation // Nature Reviews Neuroscience. 2013. Vol. 14, № 8. P. 577
  101. Nutt D. Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on “Drugs and Science” // EMBO reports. 2014. Vol. 15, № 3. P. 208-211
  102. Osmond H. A review of the clinical effects of psychotomimetic agents // Annals of the New York Academy of Sciences. 1957. Vol. 66, № 1. P. 418-434
  103. Ott J. Pharmacotheon // Natural Products Co., Kennewick, USA. 1993
  104. Pahnke W.N. Psychedelic drugs and mystical experience // International psychiatry clinics. 1969. Vol. 5, № 4. P. 149
  105. Pahnke W.N. Psychedelic drugs and mystical experience // International psychiatry clinics. 1963. Vol. 5, № 4. P. 149
  106. Pahnke W.N., Richards W.A. Implications of LSD and experimental mysticism // Journal of Religion and Health. 1966. Vol. 5, № 3. P. 175-208
  107. Passie T. et al. The pharmacology of lysergic acid diethylamide: a review // CNS Neuroscience & Therapeutics. 2008. Vol. 14, № 4. P. 295-314
  108. Passie T. et al. The pharmacology of psilocybin // Addiction biology. 2002. Vol. 7, № 4. P. 357-364
  109. Patterson D.R., Jensen M.P. Hypnosis and clinical pain // Psychological bulletin. 2003. Vol. 129, № 4. P. 495
  110. Pieri L., Pieri M., Haefely W. LSD as an agonist of dopamine receptors in the striatum // Nature. 1974. Vol. 252, № 5484. P. 586
  111. Poling A., Bryceland J. Voluntary Drug Self-Administration by Nonhumans; A Review // Journal of psychedelic drugs. 1979. Vol. 11, № 3. P. 185-190
  112. Presti D. E., Nichols D. E. Biochemistry and neuropharmacology of psilocybin mushrooms / Teonanacatl. Four Trees, El Verano, CA, 2004. P. 89-108
  113. Prue B. Indigenous supports for recovery from alcoholism and drug abuse: The Native American Church // Journal of Ethnic And Cultural Diversity in Social Work. 2013. Vol. 22, № 3-4. P. 271-287
  114. Ray T.S. Psychedelics and the human receptorome // PLoS One. 2010. Vol. 5, № 2. P. e9019
  115. Rinkel M. Pharmacodynamics of LSD and mescaline // The Journal of nervous and mental disease. 1957. Vol. 125, № 3. P. 424-426
  116. Ruck C.A., Bigwood J., Staples D. et al. Entheogens // Journal of Psychoactive Drugs. 1979. Vol. 11, № 1-2. P. 145-146
  117. Sandison R.A., Spencer A.M., Whitelaw J.D.A. The therapeutic value of lysergic acid diethylamide in mental illness // The British Journal of Psychiatry. 1954. Vol. 100, № 419. P. 491-507
  118. Savage C., McCabe O. L. Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study // Archives of General Psychiatry. 1973. Vol. 28, № 6. P. 808-814
  119. Schindler E.A.D. et al. Indoleamine hallucinogens in cluster headache: results of the Clusterbusters medication use survey // Journal of psychoactive drugs. 2015. Vol. 47, № 5. P. 372-381
  120. Schmid Y. et al. Acute effects of lysergic acid diethylamide in healthy subjects // Biological psychiatry. 2015. Vol. 78, № 8. p. 544-553
  121. Schultes R.E. Teonanácatl: The narcotic mushroom of the Aztecs // American Anthropologist. 1940. Vol. 42, № 3. P. 429-443
  122. Schultes R.E., Hofmann A. Plants of the gods: their sacred, healing, and hallucinogenic powers. 2001
  123. Schuster C.R., Thompson T. Self administration of and behavioral dependence on drugs // Annual review of pharmacology. 1969. Vol. 9, № 1. P. 483-502
  124. Sewell R.A., Halpern J.H., Pope H.G. Response of cluster headache to psilocybin and LSD // Neurology. 2006. Vol. 66, № 12. P. 1920-1922
  125. Shulgin A. T. Mescaline: The chemistry and pharmacology of its analogs // Lloydia. 1973, Vol. 36, № 1-4. P. 46-58
  126. Shulgin A.T., Nichols D.E. The Pharmacology of hallucinogens. Characteristics of three new psychotomimetics.(1stedn.). 1978
  127. Shulgin A., Shulgin A. PIHKAL: Phenethylamines I have known and loved. Transform Press, 1995
  128. Smart R.G. et al. A controlled study of lysergide in the treatment of alcoholism: I. The effects on drinking behavior // Quarterly journal of studies on alcohol. 1967
  129. Smart R.G., Storm T. The Efficacy of LSD in the Treatment of Alcoholism // QJ Stud Alcohol. 1964. Vol. 25. P. 333-338
  130. Stamets P. Psilocybin mushrooms of the world. Ten Speed Press, 1996
  131. Stoll W.A. Lysergic Acid Diethylamide, a Phantastikum from the ergot Group // Schweizer Archiv fur Neurologie und Psychiatrie. 1947. Vol. 60, № 1-2. P. 279-323
  132. Strassman R.J. Adverse reactions to psychedelic drugs. A review of the literature // J Nerv Ment Dis. 1984. Vol. 172, № 10. P. 577-595
  133. Strassman R.J. Perspectives and Prospects // The Journal of nervous and mental disease. 1995_a. Vol. 183, № 3. P. 127-138
  134. Studerus E. et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies // Journal of Psychopharmacology. 2011. Vol. 25, № 11. P. 1434-1452
  135. Studerus E. et al. Prediction of psilocybin response in healthy volunteers // PLoS One. 2012. Vol. 7, № 2. P. e30800
  136. Terracciano A. et al. Hierarchical linear modeling analyses of the NEO-PI-R scales in the Baltimore Longitudinal Study of Aging // Psychology and aging. 2005. Vol. 20, № 3. P. 493
  137. Titeler M. Radioligand binding evidence implivates the brain 5-HT2 receptor as a site-of action for LSD and phenylisopropylamine hallucinogens // Biochem Pharmacol. 1988. Vol. 36. P. 3265-3271
  138. Tupper K. W. et al. Psychedelic medicine: a re-emerging therapeutic paradigm // Canadian Medical Association Journal. 2015. Vol. 187, № 14. P. 1054-1059
  139. Van Amsterdam J. et al. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population // European Addiction Research. 2010. Vol. 16, № 4. P. 202-207
  140. Van Amsterdam J., Opperhuizen A., van den Brink W. Harm potential of magic mushroom use: a review // Regulatory toxicology and pharmacology.2011. Vol. 59, № 3. P. 423-429
  141. Vollenweider F.X. et al. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man-a PET study with [11 C] raclopride // Neuropsychopharmacology. 1999. Vol. 20, № 5. P. 424
  142. Vollenweider F.X. et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action // Neuroreport. 1998. Vol. 9, № 17. P. 3897-3902
  143. Vollenweider F.X., Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders // Nature Reviews Neuroscience. 2010. Vol. 11, № 9. P. 642
  144. Wasson R.G. The wondrous mushroom: mycolatry in Mesoamerica. McGraw-Hill, 1980. № 7
  145. Whitaker-Azmitia P.M. The discovery of serotonin and its role in neuroscience // Neuropsychopharmacology. 1999. Vol. 21, № S1. P. 2S
  146. Wolbach A.B., Miner E.J., Isbell H. Comparison of psilocin with psilocybin, mescaline and LSD-25 // Psychopharmacology. 1962. Vol. 3, № 3. P. 219-223
  147. Woolley D.W., Shaw E. A biochemical and pharmacological suggestion about certain mental disorders // Proceedings of the National Academy of Sciences. 1954_a. Vol. 40, № 4. P. 228-231
  148. Woolley D.W., Shaw E. Some neurophysiological aspects of serotonin // British medical journal. 1954_b. Vol. 2, № 4880. P. 122
  149. Woolley D.W., Shaw F.N. Evidence for the participation of serotonin in mental processes // Annals of the New York Academy of Sciences. 1957. Vol. 66, № 1. P. 649-667

Copyright (c) 2018 Asadullin A.R., Antsyborov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies